Lilly, BI win FDA approval of new diabetes drug; InVivo to collaborate with U of Miami;

 @FierceBiotech:  Teva elbows aside Valeant with $6.8B buyout deal for Cephalon. Item  | Follow @FierceBiotech

 @JohnCFierce: Wilex gets $19 million for U.S. licensing rights to renal cell cancer drug Rencarex. Story | Follow @JohnCFierce

> Eli Lilly and Boehringer Ingelheim have won FDA approval of Tradjenta, a DPP-4 enzyme inhibitor designed to treat type 2 diabetes. Story

> InVivo Therapeutics and the University of Miami are collaborating on new treatments for spinal cord injuries. Report

> Cell Therapeutics reports that the FDA has rejected its appeal of the agency's rejection of pixantrone but adds that the Office of New Drugs "disagreed with the conclusion in the Complete Response Letter that PIX301 was a failed study, which warranted application of an interim analysis statistical thresholds." Release

> Keryx says it doesn't believe that new studies will be needed to win European approval of its kidney drug Zerenex. Story

> The UK's Astex Therapeutics says it has "achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline." Astex release

Pharma News

@FiercePharma: Would Pfizer break-up leave a healthier core? News | Follow @FiercePharma

> Judge tosses Mylan suit over Lipitor. Item

> Nikkei: Teva to buy Japan's No. 3 generics maker. Report

> Valeant moves on to new M&A targets. Story

Biotech Research News

> Paralyzed man reports sensations after embryonic stem cell treatment. Article 

> Researchers can erase traumatic memories in snails ... humans next? Item

> Artificial nose can quickly sniff out bacterial infections. Story

> Cancer-fighting compounds found under the sea. News

> Newly discovered genes could lead to earlier glaucoma diagnosis. Report

>  Why was U.S. so sure it had Osama bin Laden's DNA? Story

 Manufacturing News

> Generics makers position for world domination. Story 

> ABC, Cardinal see growth in specialty pharma. Item 

> ISP passes ingredient price hikes on to drugmakers. Article 

> Bayer tweaks anti-counterfeiting tactics. Report 

> Accenture IT fix for quality misses key point. News

And Finally... A new study of itch adds to growing evidence that the chemical signals that make us want to scratch are the same signals that make us wince in pain. Report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.